Review
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Mar 15, 2019; 10(3): 154-168
Published online Mar 15, 2019. doi: 10.4239/wjd.v10.i3.154
Crosstalk between gut microbiota and antidiabetic drug action
Yevheniia Kyriachenko, Tetyana Falalyeyeva, Oleksandr Korotkyi, Nataliia Molochek, Nazarii Kobyliak
Yevheniia Kyriachenko, Tetyana Falalyeyeva, Oleksandr Korotkyi, Nataliia Molochek, Educational and Scientific Centre “Institute of Biology and Medicine”, Taras Shevchenko National University of Kyiv, Kyiv 01601, Ukraine
Nazarii Kobyliak, Endocrinology Department, Bogomolets National Medical University, Kyiv 01601, Ukraine
Author contributions: All authors contributed equally to this paper in conception and design of the study, literature review and analysis, and drafting, critical revision, editing, and providing final approval of the final version.
Supported by no dedicated source of funding.
Conflict-of-interest statement: No potential conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Nazarii Kobyliak, MD, PhD, Assistant Professor, Endocrinology Department, Bogomolets National Medical University, Pushkinska 22a str., Kyiv 01601, Ukraine. nazariikobyliak@gmail.com
Telephone: +38-44-2356005 Fax: +38-44-2356005
Received: February 17, 2019
Peer-review started: February 18, 2019
First decision: February 19, 2019
Revised: March 10, 2019
Accepted: March 11, 2019
Article in press: March 11, 2019
Published online: March 15, 2019
Abstract

Type 2 diabetes (T2D) is a disorder characterized by chronic inflated blood glucose levels (hyperglycemia), at first due to insulin resistance and unregulated insulin secretion but with tendency towards global spreading. The gut microbiota is recognized to have an influence on T2D, although surveys have not formed a clear overview to date. Because of the interactions between gut microbiota and host homeostasis, intestinal bacteria are believed to play a large role in various diseases, including metabolic syndrome, obesity and associated disease. In this review, we highlight the animal and human studies which have elucidated the roles of metformin, α-glucosidase inhibitors, glucagon-like peptide-1 agonists, peroxisome proliferator-activated receptors γ agonists, inhibitors of dipeptidyl peptidase-4, sodium/glucose cotransporter inhibitors, and other less studied medications on gut microbiota. This review is dedicated to one of the most widespread diseases, T2D, and the currently used antidiabetic drugs and most promising new findings. In general, the gut microbiota has been shown to have an influence on host metabolism, food consumption, satiety, glucose homoeostasis, and weight gain. Altered intestinal microbiota composition has been noticed in cardiovascular diseases, colon cancer, rheumatoid arthritis, T2D, and obesity. Therefore, the main effect of antidiabetic drugs is on the microbiome composition, basically increasing the short-chain fatty acids-producing bacteria, responsible for losing weight and suppressing inflammation.

Keywords: Type 2 diabetes, Gut microbiota, Metformin, α-glucosidase inhibitors, Glucagon-like peptide-1 agonists, Peroxisome proliferator-activated receptors γ agonists, Dipeptidyl peptidase-4 inhibitors, Sodium/glucose cotransporter inhibitors

Core tip: Gut microbiota was found to have an influence on host metabolism, food consumption, satiety, glucose homoeostasis, and weight gain. Altered intestinal microbiota composition has been noticed in cardiovascular diseases, colon cancer, rheumatoid arthritis, type 2 diabetes, and obesity. Therefore, the main effect of antidiabetic drugs is on the microbiome composition, basically increasing the short-chain fatty acids-producing bacteria, responsible for losing weight and suppressing the inflammation.